Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
Ampronix
Schiller

Early PET-Negative Stage I/II Hodgkin Lymphoma Patients Show Increased Risk of Early Relapse when Radiotherapy Is Not Used

By Medimaging International staff writers
Posted on 23 Apr 2014
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).
Analysis of a new study indicates an increased risk of early relapse when excluding radiotherapy in early positron emission tomography (PET) scan-negative patients with stage I/II Hodgkin’s lymphoma.

The interim analysis of the intergroup EORTC-LYSA-FIL 20051 H10 trial was published online March 17, 2014, in the Journal of Clinical Oncology. Early outcome, however, was excellent in both arms, and the final analysis should reveal whether these preliminary findings are upheld over time.

Dr. J.M.M. Raemaekers, from the Radboud University Medical Center (Nijmegen, The Netherlands), and central coordinator of the study stated, “The standard treatment for patients with clinical stage I/II Hodgkin’s lymphoma is ABVD [adriamycin, bleomycin, vinblastin and dacarbazin] chemotherapy followed by radiotherapy. Striking the right balance between initial cure through combined modality treatment and accepting a higher risk of late complications, and a higher recurrence rate after omitting radiotherapy in subsets of patients who will subsequently need intensive salvage treatment, is a matter of unsettled debate.”

The main objective of the H10 trial was to evaluate whether involved-node radiotherapy could be omitted without loss of efficacy in terms of progression-free survival in patients with stage I/II Hodgkin’s lymphoma who had a negative early PET scan after two cycles of ABVD chemotherapy. This interim trial analysis included a total of 1,137 patients with untreated clinical stage I/II Hodgkin’s lymphoma. Of these, 444 patients had favorable and 693 unfavorable prognoses. Patients in each prognostic group were randomized between standard and experimental treatment and first received two cycles of ABVD chemotherapy. Patients in the experimental arm who attained a negative early PET scan after the two cycles of ABVD chemotherapy were spared involved-node radiotherapy.

One progression occurred in the standard arm and nine progressions occurred in the research arm, for patients with a favorable prognosis and a negative early PET scan. For patients with unfavorable prognosis and a negative early PET scan, seven events occurred in the standard arm and 16 events occurred in the research arm. Even though there were few events and the median follow-up time short, the Independent Data Monitoring Committee concluded it was unlikely that the final results would show noninferiority for the experimental treatment. They, therefore, advised that randomization should be stopped for early PET-negative patients.
The study was closed for recruitment in June 2011 with a total of 1952 patients. The intergroup EORTC 20051 H10 trial is coordinated by the EORTC Lymphoma Group in collaboration with the LYmphoma Study Association (LYSA) and the Fondazione Italiana Linfomi (FIL). It is being conducted in 159 sites in eight countries: Belgium, Croatia, Denmark, France, Italy, Slovakia, Switzerland, and The Netherlands.

Related Links:

Radboud University Medical Center



Channels

Radiography

view channel

Pediatric Radiation Dose Reduction Key Factor in Selection of DR Systems

X-Ray dose reduction potential was a key factor in the decision of the Washington DC (USA) metropolitan area Children’s National Health System to install new Direct Radiography (DR) systems. The priority of Children’s National Health System was to ensure that pediatric patients would receive the lowest possible dose... Read more

MRI

view channel
Image: The Micronor M303 Encoding Sensor with A/B Quadrature Pulse Train Background (Photo courtesy of Micronor).

World’s First MRI-Safe Linear Encoder for Medical Applications Announced

A company specialized in producing fiber optic kinetic sensors, has developed a first-of-a-kind passive, optical, non-electronic, high-precision encoder for use in medical Magnetic Resonance Imaging (MRI).... Read more

Ultrasound

view channel
Image: The Lumify, app-based ultrasound system (Photo courtesy of Philips).

Philips Debuts First App-Based Ultrasound

An app-based ultrasound solution aims extending the reach of ultrasound applications using mobile technology. The app was presented at the Social Media and Critical Care conference, June, 23–26, 2015... Read more

General/Advanced Imaging

view channel

FDA Approves Trial for Intraoperative Image-Guided Cancer Surgery System

The US Food and Drug Administration (FDA) has provided Investigational Device Exemption (IDE) approval for company to trial a new image-guided cancer surgery system for intraoperative imaging of breast cancer. The surgical system consists of a cancer-specific molecular imaging agent, and a lightweight hand-held single-cell... Read more

Imaging IT

view channel
Image: Siemens radiation therapy Syngo.via image suite (Photo courtesy of Siemens Healthcare).

New Version of Syngo.via Supports Treatment Decision in Oncology

Siemens Healthcare has released a new version of oncology diagnostics software that helps physicians plan the best course of treatment for cancer patients. Cancer treatment requires comprehensive diagnostics,... Read more

Industry News

view channel
Image: The Westchester Medical Center in Valhalla, NY, USA (Photo courtesy of Business Wire).

Philips to Provide Multi-Year USD 500 Million in Healthcare Services in the USA

Royal Philips (Amsterdam, the Netherlands) and the Westchester Medical Center Health Network (WMCHealth; Valhalla, NY, USA) have announced USD 500 million multi-year partnership. Philips will provide... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.